आपके बैज 52W रेंज $70–$111 41% of range विश्लेषक रेटिंग BUY 33 analysts मूल्य लक्ष्य $116 +35% upside P/E 22.8 ROE 6.2% शुद्ध लाभ मार्जिन 1.2%

CVS स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

03
मूल्य $86.43
मार्केट कैप (MRQ) $110.46B
P/E (TTM) 22.8
EPS (TTM) $3.79
राजस्व (TTM) $415.09B
लाभांश प्रतिफल 3.1%
ROE (TTM) 6.2%
D/E ऋण/इक्विटी 0.0
52W रेंज $70–$111

CVS स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

04
सीमा
बार

बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।

स्टॉक विभाजन 4
एक्स-डेट स्प्लिट प्रकार
7 जून 2005 2-for-1 फॉरवर्ड
16 जून 1998 2-for-1 फॉरवर्ड
15 मार्च 1989 2-for-1 फॉरवर्ड
3 मई 1983 2-for-1 फॉरवर्ड

CVS Health Corporation Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

05 · wikidata

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

Privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

In September 2026, CVS entered into a $20.5 million class action settlement after a lawsuit alleged that CVS disclosed customers' personal data to advertising company Criteo.

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

क्षेत्रHealth Care उद्योगHealth Care कर्मचारी219000 देशUS

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

06
राजस्व$402.07B
2017-12-31 → 2025-12-31
EPS$1.39
2017-12-31 → 2025-12-31
फ्री कैश फ्लो$7.81B
2017-12-31 → 2025-12-31
शुद्ध मार्जिन1.2%
2017-12-31 → 2025-12-31
मूल्यांकन और अनुपात 07–12

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक 5Y रुझान CVS 5Y औसत सहकर्मी माध्यिका निर्णय
P/E (TTM) 22.85Y औसत ≈25.5 ≈25.5 23.3 अति मूल्यांकित
P/S (TTM) 0.35Y औसत ≈0.3 ≈0.3 1.3 अल्पमूल्यित
P/B (MRQ) 1.45Y औसत ≈1.4 ≈1.4 2.9 अल्पमूल्यित
EV / EBITDA 10.75Y औसत ≈6.1 ≈6.1 11.4 अल्पमूल्यित
मूल्य / FCF (TTM) 9.45Y औसत ≈9.9 ≈9.9 · ·
मूल्य / नकदी प्रवाह (TTM) 7.55Y औसत ≈7.6 ≈7.6 9.8 उचित मूल्य
EV / Revenue (EV / राजस्व) 0.25Y औसत ≈0.2 ≈0.2 · ·
EV / FCF 12.75Y औसत ≈9.3 ≈9.3 · ·
मूल्य / मूर्त पुस्तक (MRQ) 2.0 · · ·

सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।

मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय

लाभांश यील्ड, भुगतान अनुपात, लाभांश इतिहास, 5Y CAGR

13
लाभांश यील्ड3.1%
भुगतान अनुपात192.1%
वार्षिक भुगतान≈$2.66तिमाही भुगतान
5Y लाभांश CAGR≈5.9%प्रति शेयर, विभाजन-समायोजित
एक्स-डेटराशिमुद्रायील्ड
जुल 23, 2026$0.67USD≈2.5%
अप्र 23, 2026$0.67USD≈3.4%
जन 22, 2026$0.67USD≈3.2%
अक्ट 23, 2025$0.67USD≈3.3%
जुल 22, 2025$0.67USD≈4.4%
अप्र 22, 2025$0.67USD≈4.1%
जन 23, 2025$0.67USD≈4.9%
अक्ट 21, 2024$0.67USD≈4.6%
जुल 22, 2024$0.67USD≈4.5%
अप्र 19, 2024$0.67USD≈3.6%
जन 19, 2024$0.67USD≈3.4%
अक्ट 19, 2023$0.61USD≈3.4%
जुल 20, 2023$0.61USD≈3.2%
अप्र 20, 2023$0.61USD≈3.2%
जन 19, 2023$0.61USD≈2.6%
अक्ट 20, 2022$0.55USD≈2.4%
जुल 21, 2022$0.55USD≈2.3%
अप्र 21, 2022$0.55USD≈2.0%
जन 20, 2022$0.55USD≈2.0%
अक्ट 21, 2021$0.50USD≈2.3%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

14
औसत आश्चर्य 22.0%
अगली रिपोर्ट अक्ट 27, 2026
Periodरिपोर्टEPS ActualEPS अनुमानआश्चर्य
30 जून 2026 जुल 29, 2026 $2.58 $1.87 38.0%
31 मार्च 2026 $2.57 $2.22 15.8%
31 दिसमबर 2025 $1.09 $1.00 8.8%
30 सितमबर 2025 $1.60 $1.38 15.7%
30 जून 2025 $1.81 $1.47 23.0%
31 मार्च 2025 $2.25 $1.72 30.8%

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

15
आय विवरण 16
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Cost of Revenue $221.17B$206.29B$217.10B$196.89B$175.80B$163.98B$158.72B·$153.45B$146.53B$126.76B
Gross Profit ········$28.55B$28.86B$26.53B
Operating Expenses $397.41B$364.29B$344.03B$314.51B$278.80B$254.79B$244.79B·$18.81B$18.45B$17.05B
Operating Income $4.66B$8.52B$13.74B$7.95B$13.31B$13.91B$11.99B·$9.54B$10.39B$9.47B
Interest Expense ··$2.66B$2.29B$2.50B$2.91B$3.04B·$1.06B$1.08B$859M
Interest Income ········$21M$20M$21M
Other Non-op $112M$99M$88M$169M$182M$206M$124M·$-208M$-28M·
Pretax Income $2.14B$6.15B$11.17B$5.84B$10.54B$9.77B$9.00B·$8.27B$8.64B$8.62B
Income Tax $408M$1.56B$2.81B$1.51B$2.55B$2.57B$2.37B·$1.64B$3.32B$3.39B
Net Income $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
EPS (Basic) $1.40$3.67$6.49$3.29$6.07$5.48$5.10·$6.47$4.93$4.66
EPS (Diluted) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
Shares (Basic) 1,267,000,0001,259,000,0001,285,000,0001,312,000,0001,319,000,0001,309,000,0001,301,000,000·1,020,000,0001,073,000,0001,118,000,000
Shares (Diluted) 1,271,000,0001,262,000,0001,290,000,0001,323,000,0001,329,000,0001,314,000,0001,305,000,000·1,024,000,0001,079,000,0001,126,000,000
EBITDA $9.27B$13.11B$18.11B$11.99B$17.70B$18.35B$16.36B·$12.00B$10.34B$9.45B
बैलेंस शीट 31
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Cash & Equivalents $8.45B$8.59B$8.20B$12.95B$9.41B$7.85B$5.68B·$1.70B$3.37B$2.46B
Short-term Investments $2.15B$2.41B$3.26B$2.78B$3.12B$3.00B$2.37B·$111M$87M$88M
Receivables $39.78B$36.47B$35.23B$27.28B$24.43B$21.74B$19.62B·$13.18B$12.16B$11.89B
Inventory $19.25B$18.11B$18.02B$19.09B$17.76B$18.50B$17.52B·$15.30B$14.76B$14.00B
Other Current Assets $5.09B$3.08B$3.15B$2.64B$5.29B$5.28B$5.11B$4.53B$945M$660M$722M
Current Assets $74.71B$68.64B$67.86B$65.63B$60.01B$56.37B$50.30B$45.20B$31.23B$31.04B$29.16B
PP&E (Net) ···$12.87B$12.90B$12.61B$12.04B$11.36B$10.29B$10.18B$9.86B
PP&E (Gross) ···$34.60B$33.55B$31.31B$28.93B·$24.29B$22.80B$21.04B
Accum. Depreciation ···$21.48B$20.65B$18.70B$16.89B·$14.00B$12.63B$11.18B
Goodwill $85.48B$91.27B$91.27B$78.15B$79.12B$79.55B$79.75B·$38.45B$38.25B$38.11B
Intangibles $25.51B$27.32B$29.23B$24.80B$29.03B$31.14B$33.12B$36.31B$13.63B$13.51B$13.88B
Other Non-current Assets $7.11B$4.79B$4.66B$4.62B$4.71B$4.62B$4.60B$4.53B$1.42B$1.49B$1.44B
Total Assets $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B$216.67B$95.13B$94.46B$92.44B
Accounts Payable ········$8.86B$7.95B$7.49B
Accrued Liabilities $22.39B$20.81B$23.52B$18.75B$17.67B$14.24B$12.13B$10.66B$6.58B$6.94B$6.83B
Short-term Debt $0$2.12B$200M$0·$0$0·$1.28B$1.87B$0
Current Liabilities $88.69B$84.61B$79.19B$69.42B$67.81B$62.02B$53.30B$45.76B$30.65B$26.25B$23.17B
Capital Leases $13.64B$14.90B$16.03B$16.80B$18.18B$18.76B$18.93B$18.83B$306M··
Deferred Tax $3.83B$3.81B$4.31B$4.02B$6.27B$6.79B$7.29B$7.74B$3.00B$4.21B$4.22B
Other Non-current Liabilities $6.77B$5.43B$6.21B$6.73B$1.90B$2.35B$2.16B$2.26B$1.28B$1.55B$1.54B
Total Liabilities $178.16B$177.49B$173.09B$156.51B$157.62B$161.01B$158.28B$157.95B$57.44B··
Long-term Debt ······$68.48B$72.61B$27.00B$25.70B$27.50B
Total Debt $0$2.12B$200M···$3.78B·$27.00B$27.53B$27.46B
Common Stock ·$18M$18M$18M$17M$17M$17M·$17M$17M$17M
Paid-in Capital ········$32.08B$31.62B$30.95B
Retained Earnings $61.20B$62.84B$61.60B$56.40B$54.91B$49.64B$45.11B$41.09B$43.56B$38.98B$35.51B
Treasury Stock $36.79B$36.82B$33.84B$31.86B$28.17B$28.18B$28.23B·$37.80B$33.45B$28.89B
AOCI $406M$-120M$-297M$-1.26B$965M$1.41B$1.02B·$-165M$-305M$-358M
Stockholders' Equity $75.21B$75.56B$76.46B$71.47B$75.08B$69.39B$63.86B$58.40B$37.69B$36.83B$37.20B
Liabilities + Equity $253.54B$253.22B$249.73B$228.28B$233.00B$230.72B$222.45B·$95.13B$94.46B$92.44B
Shares Outstanding 1,271,000,0001,260,000,0001,288,000,0001,300,000,0001,322,000,0001,310,000,0001,302,000,000·1,712,000,0001,061,000,0001,101,000,000
नकदी प्रवाह 19
मेट्रिक रुझान 20252024202320222021202020192018201720162015
D&A $4.61B$4.60B$4.37B$4.22B$4.49B$4.44B$4.37B·$2.48B$2.48B$2.09B
Stock-based Comp $535M$540M$588M$447M$484M$400M$453M·$234M$222M$230M
Deferred Tax $102M$-572M$-676M$-2.03B$-402M$-564M$-649M·$-1.42B$3M$-234M
Amort. of Intangibles $2.00B$2.00B$1.90B$1.80B$2.20B$2.30B$2.40B·$817M$795M$611M
Restructuring ········$215M··
Other Non-cash $3.63B$-72M$804M$9.41B$5.79B$4.41B$2.04B·$93M··
Operating Cash Flow $10.64B$9.11B$13.43B$16.18B$18.27B$15.87B$12.85B·$8.01B$10.14B$8.54B
CapEx $2.83B$2.78B$3.03B$2.73B$2.52B$2.44B$2.46B·$1.92B$2.22B$2.37B
Investing Cash Flow $-5.87B$-7.61B$-20.89B$-5.05B$-5.26B$-5.53B$-3.34B·$-2.88B$-2.47B$-13.42B
Debt Issued $3.97B$7.91B$10.90B$0$987M$9.96B$3.74B·$0$3.46B$14.80B
Net Debt Issued $340M$3.14B$7.73B$-4.21B$-9.27B$-5.67B$-4.60B··$-2.49B$11.90B
Stock Repurchased $0$3.02B$2.01B$3.50B$0$0$0·$4.36B$4.46B$5.00B
Net Stock Activity $0$-3.02B$-2.01B$-3.50B··$0·$-4.36B$-4.46B$-5.00B
Dividends Paid $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B
Financing Cash Flow $-4.94B$-1.14B$2.68B$-10.52B$-11.36B$-7.70B$-7.65B·$-6.75B$-6.76B$4.88B
Net Change in Cash $-172M$359M$-4.78B$614M$1.65B$2.63B$1.85B·$-1.62B$912M$-22M
Taxes Paid $2.17B$1.70B$3.52B$4.12B$3.19B$2.93B$2.72B·$2.91B$3.06B$3.27B
Free Cash Flow $7.81B$6.33B$10.39B$13.45B$15.74B$13.43B$10.39B·$6.09B$7.84B$6.04B
Levered FCF ··$8.40B$11.76B$13.85B$11.29B$8.15B·$5.24B$7.18B$5.52B
लाभप्रदता 8
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Gross Margin ········15.4%16.3%17.3%
Operating Margin 1.2%2.3%3.8%2.4%4.5%5.2%4.7%·5.1%5.8%6.2%
Net Margin 0.44%1.2%2.3%1.3%2.7%2.7%2.6%·3.6%3.0%3.4%
Pretax Margin 0.53%1.7%3.1%1.8%3.6%3.6%3.5%·4.5%4.9%5.6%
EBITDA Margin 2.3%3.5%5.1%3.7%6.1%6.8%6.4%·6.5%5.8%6.2%
ROA 0.70%1.8%3.5%1.8%3.4%3.2%3.0%·7.0%5.7%6.2%
ROE 2.4%6.1%11.3%5.7%10.9%10.8%10.8%·17.8%14.4%13.9%
ROIC 5.0%8.2%13.4%8.1%13.3%14.8%13.1%·11.8%9.9%8.9%
तरलता और शोधन क्षमता 5
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Current Ratio 0.80.80.90.90.90.90.9·1.01.21.3
Quick Ratio 0.60.60.60.60.50.50.5·0.50.60.6
Debt / Equity 0.00.00.0···0.1·0.70.70.7
LT Debt / Equity ········0.60.70.7
Interest Coverage ··5.23.45.34.83.9·9.09.611.0
दक्षता 3
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Asset Turnover 1.61.51.51.41.31.21.2·1.91.91.8
Inventory Turnover 11.811.411.710.79.79.19.3·10.410.39.8
Receivables Turnover 10.510.411.412.512.713.013.8·14.614.814.2
प्रति शेयर 7
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Book Value / Share $59.18$59.97$59.36$54.63$56.79$52.97$49.05·$37.17$34.71$33.78
Revenue / Share $316.34$295.41$277.35$243.74$219.80$204.49$196.76·$180.43$164.53$136.14
Cash Flow / Share $8.37$7.22$10.41$12.23$13.74$12.07$9.85·$7.82$9.33$7.47
Cash / Share $6.65$6.81$6.36$9.96$7.12$6.00$4.36·$1.67$3.18$2.23
Dividend / Share $2.66$2.66$2.42$2.20$2.00$2.00$2.00·$2.00$1.70$1.40
Dividend Paid / Share ········$2.00··
EPS (TTM) $1.39$3.66$6.47$3.26$6.02$5.46$5.08·$6.44$4.90$4.63
विकास दरें 10
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue YoY 7.8%4.2%10.9%10.4%8.7%······
Revenue CAGR 3Y 7.6%8.5%10.0%········
Revenue CAGR 5Y 8.4%··········
EPS YoY -62.0%-43.4%98.5%-45.9%10.3%······
EPS CAGR 3Y -24.7%-15.3%5.8%········
EPS CAGR 5Y -23.9%··········
Net Income YoY -61.7%-44.7%93.5%-46.1%11.5%······
Net Income CAGR 3Y -25.7%-16.8%5.1%········
Net Income CAGR 5Y -24.4%··········
Dividends Paid CAGR 5Y 5.3%··········
मूल्यांकन (TTM) 16
मेट्रिक रुझान 20252024202320222021202020192018201720162015
Revenue TTM $402.07B$372.81B$357.78B$322.47B$292.11B$268.71B$256.78B·$184.79B$177.55B$153.29B
Net Income TTM $1.77B$4.61B$8.34B$4.31B$8.00B$7.18B$6.63B·$6.62B$5.32B$5.24B
Market Cap $100.87B$56.56B$101.70B$121.15B$136.38B$89.47B$96.73B·$73.52B$83.72B$107.64B
Enterprise Value $90.27B$47.69B$90.45B···$92.45B·$98.71B$107.80B$132.56B
P/E 57.112.312.228.617.112.514.6·11.316.121.1
P/S 0.30.20.30.40.50.30.4·0.40.50.7
P/B 1.30.71.31.71.81.31.5·2.02.32.9
P / Cash Flow 9.56.27.67.57.55.67.5·9.28.312.8
P / FCF 12.98.99.89.08.76.79.3·12.110.717.8
EV / EBITDA 9.73.65.0···5.7·8.210.414.0
EV / FCF 11.67.58.7···8.9·16.213.721.9
EV / Revenue 0.20.10.3···0.4·0.50.60.9
Dividend Yield 3.4%6.0%3.1%2.4%1.9%2.9%2.7%·2.8%2.2%1.5%
Earnings Yield 1.8%8.2%8.2%3.5%5.8%8.0%6.8%·8.9%6.2%4.7%
Payout Ratio 192.1%73.1%37.5%70.1%33.2%36.5%39.2%·30.9%34.6%30.1%
Annual Payout $3.40B$3.37B$3.13B$2.91B$2.62B$2.62B$2.60B·$2.05B$1.84B$1.58B

सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

16
मेट्रिक 2025-12-312024-12-312023-12-312022-12-312021-12-31
राजस्व $402.07B $372.81B $357.78B $322.47B $292.11B
परिचालन मार्जिन % 1.2% 2.3% 3.8% 2.4% 4.5%
शुद्ध आय $1.77B $4.61B $8.34B $4.31B $8.00B
तनुकरणित EPS $1.39 $3.66 $6.47 $3.26 $6.02

संस्थागत मालिक (13F) 2275 फाइलर्स · $125.7B कुल · तिथि अनुसार 30 सितमबर 2026

17

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

धारक 2275
धारित मूल्य $125.7B
नई स्थितियाँ 314
बाहर निकली पोजीशन 93
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
314 (+117 पिछली तिमाही की तुलना में) 93 (-96 पिछली तिमाही की तुलना में) 799 (+75 पिछली तिमाही की तुलना में) 755 (-20 पिछली तिमाही की तुलना में) +50.0M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
BlackRock, Inc. $12747461705 123223409 10.15% शेयर
VANGUARD GROUP INC $9579508282 120709530 7.62% शेयर
VANGUARD CAPITAL MANAGEMENT LLC $8618974924 83315369 6.86% शेयर
Capital World Investors $7753834783 74951955 6.17% शेयर
STATE STREET CORP $6236318558 60283408 4.96% शेयर
Dodge & Cox $5173820539 50012765 4.12% शेयर
WELLINGTON MANAGEMENT GROUP LLP $3496725140 33801113 2.78% शेयर
GEODE CAPITAL MANAGEMENT, LLC $3079404427 29899653 2.45% शेयर
FMR LLC $2991837927 28920617 2.38% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $2755624444 26637259 2.19% शेयर
Capital Research Global Investors $2516851376 24329151 2.00% शेयर
BANK OF AMERICA CORP /DE/ $2398868007 23188670 1.91% शेयर
JPMORGAN CHASE & CO $2290461677 22112970 1.82% शेयर
Invesco Ltd. $2130597379 20595431 1.70% शेयर
MORGAN STANLEY $1924793937 18606028 1.53% शेयर
NORGES BANK $1866126481 18038922 1.49% शेयर
Capital International Investors $1591868430 15387600 1.27% शेयर
GOLDMAN SACHS GROUP INC $1387451459 13411807 1.10% शेयर
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $1371677011 13259314 1.09% शेयर
Davis Selected Advisers $1227594458 11865916 0.98% शेयर
PZENA INVESTMENT MANAGEMENT LLC $1217558500 11769536 0.97% शेयर
NORTHERN TRUST CORP $1186760815 11471830 0.94% शेयर
FRANKLIN RESOURCES INC $1032982350 9985330 0.82% शेयर
Legal & General Group Plc $948946746 9172999 0.76% शेयर
Bank of New York Mellon Corp $932453862 9013571 0.74% शेयर
Clearbridge Investments, LLC $883116767 8536952 0.70% शेयर
ROYAL BANK OF CANADA $880475000 8511113 0.70% शेयर
GQG Partners LLC $822989370 7955411 0.65% शेयर
AMERIPRISE FINANCIAL INC $821911618 7943034 0.65% शेयर
Amundi $778468900 7525080 0.62% शेयर
DIMENSIONAL FUND ADVISORS LP $763688490 7381983 0.61% शेयर
VANGUARD FIDUCIARY TRUST CO $741242940 7165229 0.59% शेयर
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $595969397 8298098 0.47% शेयर
Nuveen, LLC $544750652 5265836 0.43% शेयर
UBS Group AG $544267107 5261161 0.43% शेयर
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524415257 5069263 0.42% शेयर
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main $511339969 4942871 0.41% शेयर
GLENVIEW CAPITAL MANAGEMENT, LLC $499125457 4824799 0.40% शेयर
CITADEL ADVISORS LLC $497856229 4812530 0.40% शेयर
DEUTSCHE BANK AG\ $466633571 4510716 0.37% शेयर
RAYMOND JAMES FINANCIAL INC $449870951 4348680 0.36% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $409796485 3961300 0.33% कॉल ऑप्शन
Allianz Asset Management GmbH $391245314 3781975 0.31% शेयर
WELLS FARGO & COMPANY/MN $380921357 3682178 0.30% शेयर
VIKING GLOBAL INVESTORS LP $378974695 3663361 0.30% शेयर
Swiss National Bank $371195152 3588160 0.30% शेयर
National Pension Service $352166145 3404216 0.28% शेयर
Mitsubishi UFJ Asset Management Co., Ltd. $322653390 3118927 0.26% शेयर
Russell Investments Group, Ltd. $312682898 3022292 0.25% शेयर
Holocene Advisors, LP $310524210 3001684 0.25% शेयर

सभी 2275 संस्थागत मालिक दिखाएँ →

कार्यकर्ता और 5%+ मालिक 1 होल्डिंग

18

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
CVS Caremark Corporation 7 जनवरी 2011 · प्रारंभिक फाइलिंग M&A / बिक्री SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

कंपनी के अंदरूनी सूत्र 86 इनसाइडर्स · 48 अधिकारी · 41 निदेशक

19
अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
David J. Joyner President, CEO and Chair 1 अप्रैल 2026 F 70349 0 0 $0
Karen S Lynch President and CEO 1 अप्रैल 2024 A 74687 0 0 $0
Brian Newman EVP, Chief Financial Officer 31 मई 2026 F 3008 0 0 $0
Thomas F. Cowhey EVP and CFO 1 अप्रैल 2025 A 41109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer 1 अप्रैल 2023 A 34706 0 0 $0
Eva C Boratto EVP & CFO 4 मई 2021 S 115331 0 0 $0
David M Denton EVP and CFO 29 नवमबर 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer 14 दिसमबर 2009 M 207179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv 2 नवमबर 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer 1 अप्रैल 2022 A 426025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer 26 जून 2026 F 27606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer 31 मई 2026 F 9557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer 8 मई 2026 S 10133 0 1 $-6230379
Prem S Shah EVP and Group President 31 मार्च 2026 A 64356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer 31 मार्च 2026 A 13023 3 0 $4588
Samrat S. Khichi EVP, CPO and General Counsel 31 मार्च 2026 A 33421 0 0 $0
Steven H Nelson EVP and President, Aetna 31 मार्च 2026 A 2900 1 0 $1289
Sreekanth K Chaguturu EVP and Chief Medical Officer 1 अप्रैल 2024 A 23666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer 1 अप्रैल 2024 A 9426 0 0 $0
Brian A Kane EVP/President, Aetna 1 अप्रैल 2024 A 12569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits 1 अप्रैल 2023 A 35068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail 1 अप्रैल 2023 A 124383 0 0 $0
Thomas M Moriarty EVP & General Counsel 31 दिसमबर 2022 F 315273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices 4 अगस्त 2022 M 109183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer 3 अप्रैल 2022 F 232676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail 1 अप्रैल 2021 A 29502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer 1 अप्रैल 2021 F 66417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL 28 फ़रवरी 2021 F 25657 0 0 $0
Jonathan E. Mayhew EVP - Transformation 2 दिसमबर 2020 F 6855 0 0 $0
Derica W Rice EVP & President, CVS Caremark 28 फ़रवरी 2020 F 26827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy 1 अप्रैल 2019 A 15237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy 16 फ़रवरी 2018 M 45107 0 0 $0
Robert O. Kraft EVP and President - Omnicare 3 अप्रैल 2017 A 92360 0 0 $0
Andrew Sussman EVP, Clinical Services 3 अप्रैल 2017 A 16433 0 0 $0
Stephen J Gold EVP & CIO 3 अप्रैल 2017 A 46818 0 0 $0
Per Gh Lofberg EVP 2 जनवरी 2015 M 23419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy 30 सितमबर 2013 M 45955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer 1 अप्रैल 2013 A 17845 0 0 $0
Douglas A Sgarro EVP and CLO 11 मई 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO 16 मार्च 2012 M 10967 0 0 $0
Thomas M Ryan Non-Executive Chairman 3 अप्रैल 2011 F 1156702 0 0 $0
Sara Finley SVP, Gen Counsel 18 फ़रवरी 2011 F 29053 0 0 $0
Michael V Ferdinandi Senior Vice President 19 अगस्त 2009 S 16021 0 0 $0
Paula A Price Controller 12 फ़रवरी 2008 A 16498 0 0 $0
Edwin M Crawford Chairman 29 अक्टूबर 2007 A 135572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services 18 जून 2007 M 182 0 0 $0
Gregory S Weishar Vice President 3 अप्रैल 2006 A 30161 0 0 $0
Larry D Solberg Senior Vice President 16 फ़रवरी 2006 A 5978 0 0 $0
ROBBINS LARRY निदेशक 21 मई 2026 S 4824799 0 8 $-352750556
Fernando Aguirre निदेशक 21 मई 2026 D 10513 0 0 $0
Jeffrey R. Balser निदेशक 14 मई 2026 A 15717 0 0 $0
Douglas H. Shulman निदेशक 14 मई 2026 A 5929 0 0 $0
Leslie V Norwalk निदेशक 14 मई 2026 A 7376 0 0 $0
Michael F Mahoney निदेशक 14 मई 2026 A 6345 0 0 $0
Anne A. Finucane निदेशक 14 मई 2026 A 591 0 0 $0
John E Gallina निदेशक 14 मई 2026 A 582 0 0 $0
Guy P Sansone निदेशक 14 मई 2026 A 15106 0 0 $0
Scott J Kirby निदेशक 14 मई 2026 A 14434 0 0 $0
DECOUDREAUX ALECIA A निदेशक 14 मई 2026 A 2970 0 0 $0
David C Brown II निदेशक 14 मई 2026 A 129316 0 0 $0
Roger N Farah निदेशक 30 नवमबर 2025 F 19438 0 0 $0
Mary L Schapiro निदेशक 21 नवमबर 2024 A 7585 0 0 $0
Jean Pierre Millon निदेशक 21 नवमबर 2024 A 4514 0 0 $0
Nancy Ann Deparle निदेशक 21 नवमबर 2024 A 34169 0 0 $0
Edward J Ludwig निदेशक 2 मई 2024 P 21630 0 0 $0
William C Weldon निदेशक 17 नवमबर 2022 A 1591 0 0 $0
Tony L White निदेशक 11 मई 2022 A 37852 0 0 $0
David W Dorman निदेशक 11 मई 2022 A 109875 0 0 $0
Larry J Merlo निदेशक 31 मई 2021 F 632313 0 0 $0
Mark T Bertolini निदेशक 20 नवमबर 2019 A 13773 0 0 $0
Richard M Bracken निदेशक 20 नवमबर 2019 A 15348 0 0 $0
Richard J Swift निदेशक 20 नवमबर 2019 A 7336 0 0 $0
Kristen Gibney Williams निदेशक 9 मई 2013 A 1695 0 0 $0
C A Piccolo निदेशक 14 दिसमबर 2012 S 181461 0 0 $0
Marian L Heard निदेशक 8 नवमबर 2012 A 11346 0 0 $0
Edwin M Banks निदेशक 15 मार्च 2012 M 23187 0 0 $0
Terrence Murray निदेशक 2 नवमबर 2011 A 84140 0 0 $0
Sheli Z Rosenberg निदेशक 4 नवमबर 2010 A 125112 0 0 $0
JOYCE WILLIAM H निदेशक 4 नवमबर 2010 A 18390 0 0 $0
Roger L Headrick निदेशक 23 मई 2007 P 2200 0 0 $0
Alfred J Verrecchia निदेशक 7 मार्च 2007 A 0 0 0 $0
Don W Cornwell निदेशक 22 दिसमबर 2006 A · 0 0 $0
Thomas P Gerrity निदेशक 9 नवमबर 2006 A 68460 0 0 $0
Stanley P Goldstein निदेशक 11 मई 2006 J 590967 0 0 $0
Terry R Lautenbach निदेशक 21 मई 2004 A 27915 0 0 $0
Chris W Bodine · 18 फ़रवरी 2009 A 23132 0 0 $0

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

ईटीएफ स्वामित्व 155 ETFs द्वारा धारित

20

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
IHF · iShares Trust 13.37% 1839467 SH 11 सितमबर 2026 दैनिक
DUSA · Davis Fundamental ETF Trust 5.28% 642932 NS 31 जुलाई 2026 N-PORT
GEND · Spinnaker ETF Series 4.47% 2080 NS 31 जुलाई 2026 N-PORT
IYK · iShares Trust 4.25% 617818 SH 11 सितमबर 2026 दैनिक
CVGD · Elevation Series Trust 4.14% 54893 NS 31 जुलाई 2026 N-PORT
FMTM · EA Series Trust 3.17% 76503 NS 31 जुलाई 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2.83% 2458 NS 31 जुलाई 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2.70% 158312 NS 31 जुलाई 2026 N-PORT
SPDV · ETF Series Solutions 2.29% 28879 NS 31 जुलाई 2026 N-PORT
VHT · VANGUARD WORLD FUND 1.94% 3824297 SH 19 अगस्त 2026 दैनिक
FHLC · FIDELITY COVINGTON TRUST 1.92% 605189 NS 31 जुलाई 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 1.92% 2171907 SH 5 अक्टूबर 2026 दैनिक
RPV · Invesco Exchange-Traded Fund Trust 1.78% 341185 SH 5 अक्टूबर 2026 दैनिक
REVS · Columbia ETF Trust I 1.68% 53828 NS 31 जुलाई 2026 N-PORT
IXJ · iShares Trust 1.54% 670400 SH 11 सितमबर 2026 दैनिक
CURE · Direxion Shares ETF Trust 1.53% 25107 NS 31 जुलाई 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1.49% 151226 SH 5 अक्टूबर 2026 दैनिक
PWV · Invesco Exchange-Traded Fund Trust 1.41% 298623 SH 5 अक्टूबर 2026 दैनिक
SPVM · Invesco Exchange-Traded Fund Trust 1.39% 21140 SH 5 अक्टूबर 2026 दैनिक
DVY · iShares Trust 1.37% 3384928 SH 11 सितमबर 2026 दैनिक
VLUE · iShares Trust 1.35% 1359538 SH 11 सितमबर 2026 दैनिक
CVAR · ETF Opportunities Trust 1.21% 4966 NS 31 जुलाई 2026 N-PORT
GURU · Global X Funds 1.19% 6951 NS 31 जुलाई 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1.14% 40284000 5 अक्टूबर 2026 दैनिक
RECS · Columbia ETF Trust I 1.09% 610992 NS 31 जुलाई 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1.04% 31197000 5 अक्टूबर 2026 दैनिक
FEUS · FlexShares Trust 0.97% 10395 NS 31 जुलाई 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.95% 77895 SH 19 अगस्त 2026 दैनिक
EQWL · Invesco Exchange-Traded Fund Trust 0.92% 295567 SH 5 अक्टूबर 2026 दैनिक
FXG · First Trust Exchange-Traded AlphaDE… 0.82% 18035 NS 31 जुलाई 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0.81% 90467 SH 5 अक्टूबर 2026 दैनिक
LSEQ · Harbor ETF Trust 0.80% 1171 NS 31 जुलाई 2026 N-PORT
FTLS · First Trust Exchange-Traded Fund III 0.80% 190028 NS 31 जुलाई 2026 N-PORT
VFMF · VANGUARD WELLINGTON FUND 0.75% 50750 SH 19 अगस्त 2026 दैनिक
MTUM · iShares Trust 0.75% 1909551 SH 11 सितमबर 2026 दैनिक
UPSD · ETF Series Solutions 0.74% 8286 NS 31 जुलाई 2026 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0.72% 12142 NS 31 जुलाई 2026 N-PORT
WLDR · Two Roads Shared Trust 0.71% 6228 NS 31 जुलाई 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0.70% 20507000 5 अक्टूबर 2026 दैनिक
BSCR · Invesco Exchange-Traded Self-Indexe… 0.67% 31166000 5 अक्टूबर 2026 दैनिक
CATH · Global X Funds 0.63% 78905 NS 31 जुलाई 2026 N-PORT
GSY · Invesco Actively Managed Exchange-T… 0.63% 24935000 5 अक्टूबर 2026 दैनिक
SPMO · Invesco Exchange-Traded Fund Trust … 0.62% 1687134 SH 5 अक्टूबर 2026 दैनिक
MGV · VANGUARD WORLD FUND 0.62% 801966 SH 19 अगस्त 2026 दैनिक
LSVD · ADVISORS' INNER CIRCLE FUND 0.58% 36106 NS 31 जुलाई 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0.57% 900 NS 31 जुलाई 2026 N-PORT
PFIG · Invesco Exchange-Traded Fund Trust … 0.55% 715000 5 अक्टूबर 2026 दैनिक
VYM · VANGUARD WHITEHALL FUNDS 0.55% 5122611 SH 19 अगस्त 2026 दैनिक
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0.50% 40184 NS 31 जुलाई 2026 N-PORT
VTV · VANGUARD INDEX FUNDS 0.49% 12134319 SH 19 अगस्त 2026 दैनिक
DFUV · Dimensional ETF Trust 0.48% 710848 NS 31 जुलाई 2026 N-PORT
DFLV · Dimensional ETF Trust 0.47% 302533 NS 31 जुलाई 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0.46% 529303 SH 5 अक्टूबर 2026 दैनिक
BSCT · Invesco Exchange-Traded Self-Indexe… 0.46% 13367000 5 अक्टूबर 2026 दैनिक
IWX · iShares Trust 0.45% 185452 SH 11 सितमबर 2026 दैनिक
VOOV · VANGUARD ADMIRAL FUNDS 0.45% 293814 SH 19 अगस्त 2026 दैनिक
IVE · iShares Trust 0.41% 2119397 SH 11 सितमबर 2026 दैनिक
DIVB · iShares Trust 0.41% 87120 SH 11 सितमबर 2026 दैनिक
CHRI · Global X Funds 0.41% 310 NS 31 जुलाई 2026 N-PORT
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0.40% 17702 NS 31 जुलाई 2026 N-PORT
IUSV · iShares Trust 0.39% 1116077 SH 11 सितमबर 2026 दैनिक
VONV · VANGUARD SCOTTSDALE FUNDS 0.37% 774792 SH 19 अगस्त 2026 दैनिक
ESG · FlexShares Trust 0.37% 4650 NS 31 जुलाई 2026 N-PORT
ILCV · iShares Trust 0.35% 49213 SH 11 सितमबर 2026 दैनिक
IWD · iShares Trust 0.33% 2852019 SH 11 सितमबर 2026 दैनिक
GLBL · Pacer Funds Trust 0.32% 34 NS 31 जुलाई 2026 N-PORT
EGLE · Global X Funds 0.31% 65 NS 31 जुलाई 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0.30% 57429 SH 19 अगस्त 2026 दैनिक
OEF · iShares Trust 0.26% 540125 SH 11 सितमबर 2026 दैनिक
INFO · Harbor ETF Trust 0.25% 20350 NS 31 जुलाई 2026 N-PORT
MGC · VANGUARD WORLD FUND 0.25% 255122 SH 19 अगस्त 2026 दैनिक
ESGV · VANGUARD WORLD FUND 0.23% 290253 SH 19 अगस्त 2026 दैनिक
TOPC · iShares Trust 0.23% 777 SH 11 सितमबर 2026 दैनिक
IWL · iShares Trust 0.22% 49933 SH 11 सितमबर 2026 दैनिक
VV · VANGUARD INDEX FUNDS 0.21% 1490162 SH 19 अगस्त 2026 दैनिक
XYLD · Global X Funds 0.21% 64877 NS 31 जुलाई 2026 N-PORT
XTR · Global X Funds 0.21% 96 NS 31 जुलाई 2026 N-PORT
XVV · iShares Trust 0.21% 14653 SH 11 सितमबर 2026 दैनिक
EUSA · iShares, Inc. 0.21% 41666 SH 11 सितमबर 2026 दैनिक
XRMI · Global X Funds 0.21% 990 NS 31 जुलाई 2026 N-PORT
PTLC · Pacer Funds Trust 0.21% 64355 NS 31 जुलाई 2026 N-PORT
DFSU · Dimensional ETF Trust 0.21% 44781 NS 31 जुलाई 2026 N-PORT
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0.20% 174338 NS 31 जुलाई 2026 N-PORT
BKLC · BNY Mellon ETF Trust 0.20% 106735 NS 31 जुलाई 2026 N-PORT
XYLG · Global X Funds 0.20% 1250 NS 31 जुलाई 2026 N-PORT
VOTE · TCW ETF Trust 0.20% 21382 NS 31 जुलाई 2026 N-PORT
ADME · ETF Series Solutions 0.20% 5697 NS 31 जुलाई 2026 N-PORT
XCLR · Global X Funds 0.20% 69 NS 31 जुलाई 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0.20% 33144255 SH 19 अगस्त 2026 दैनिक
TOV · EA Series Trust 0.20% 5061 NS 31 जुलाई 2026 N-PORT
ACIO · ETF Series Solutions 0.20% 44949 NS 31 जुलाई 2026 N-PORT
LRGF · iShares Trust 0.20% 76567 SH 11 सितमबर 2026 दैनिक
QVML · Invesco Exchange-Traded Fund Trust … 0.20% 38099 SH 5 अक्टूबर 2026 दैनिक
DFUS · Dimensional ETF Trust 0.19% 389482 NS 31 जुलाई 2026 N-PORT
VOXP · Advisors Series Trust 0.19% 108 NS 31 जुलाई 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0.19% 4814 NS 31 जुलाई 2026 N-PORT
VONE · VANGUARD SCOTTSDALE FUNDS 0.19% 212337 SH 19 अगस्त 2026 दैनिक
QDPL · Pacer Funds Trust 0.19% 30732 NS 31 जुलाई 2026 N-PORT
EVUS · iShares Trust 0.19% 7499 SH 11 सितमबर 2026 दैनिक
IVV · iShares Trust 0.19% 16082099 SH 11 सितमबर 2026 दैनिक
RSP · Invesco Exchange-Traded Fund Trust 0.18% 2040870 SH 5 अक्टूबर 2026 दैनिक
SIZE · iShares Trust 0.18% 8166 SH 11 सितमबर 2026 दैनिक
FEX · First Trust Exchange-Traded AlphaDE… 0.18% 27242 NS 31 जुलाई 2026 N-PORT
ILCB · iShares Trust 0.18% 24548 SH 11 सितमबर 2026 दैनिक
VTI · VANGUARD INDEX FUNDS 0.18% 40509855 SH 19 अगस्त 2026 दैनिक
VTHR · VANGUARD SCOTTSDALE FUNDS 0.18% 108067 SH 19 अगस्त 2026 दैनिक
IWB · iShares Trust 0.17% 888287 SH 11 सितमबर 2026 दैनिक
IYY · iShares Trust 0.17% 54746 SH 11 सितमबर 2026 दैनिक
USCL · iShares Trust 0.17% 50655 SH 11 सितमबर 2026 दैनिक
FTA · First Trust Exchange-Traded AlphaDE… 0.17% 22631 NS 31 जुलाई 2026 N-PORT
PBP · Invesco Exchange-Traded Fund Trust 0.17% 7610 SH 5 अक्टूबर 2026 दैनिक
IWV · iShares Trust 0.17% 354060 SH 11 सितमबर 2026 दैनिक
TILT · FlexShares Trust 0.17% 34918 NS 31 जुलाई 2026 N-PORT
DCOR · Dimensional ETF Trust 0.17% 53112 NS 31 जुलाई 2026 N-PORT
DFAU · Dimensional ETF Trust 0.17% 197043 NS 31 जुलाई 2026 N-PORT
ITOT · iShares Trust 0.17% 1661154 SH 11 सितमबर 2026 दैनिक
PBUS · Invesco Exchange-Traded Fund Trust … 0.17% 205413 SH 5 अक्टूबर 2026 दैनिक
HCMT · Direxion Shares ETF Trust 0.16% 8880 NS 31 जुलाई 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0.16% 15103 SH 5 अक्टूबर 2026 दैनिक
ACVF · ETF Opportunities Trust 0.16% 2271 NS 31 जुलाई 2026 N-PORT
DYNF · BlackRock ETF Trust 0.16% 675214 SH 11 सितमबर 2026 दैनिक
SPXL · Direxion Shares ETF Trust 0.15% 99749 NS 31 जुलाई 2026 N-PORT
TOK · iShares Trust 0.14% 3579 SH 11 सितमबर 2026 दैनिक
PHDG · Invesco Actively Managed Exchange-T… 0.14% 1007 SH 5 अक्टूबर 2026 दैनिक
URTH · iShares, Inc. 0.13% 114536 SH 11 सितमबर 2026 दैनिक
OMFL · Invesco Exchange-Traded Self-Indexe… 0.13% 70115 SH 5 अक्टूबर 2026 दैनिक
DFAC · Dimensional ETF Trust 0.12% 539188 NS 31 जुलाई 2026 N-PORT
ACWI · iShares Trust 0.12% 406018 SH 11 सितमबर 2026 दैनिक
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.11% 1069623 SH 19 अगस्त 2026 दैनिक
DXUV · Dimensional ETF Trust 0.10% 5157 NS 31 जुलाई 2026 N-PORT
QLC · FlexShares Trust 0.09% 8960 NS 31 जुलाई 2026 N-PORT
FAB · First Trust Exchange-Traded AlphaDE… 0.08% 1368 NS 31 जुलाई 2026 N-PORT
CRBN · iShares Trust 0.05% 6619 SH 11 सितमबर 2026 दैनिक
FBCG · FIDELITY COVINGTON TRUST 0.05% 35048 NS 31 जुलाई 2026 N-PORT
GLOF · iShares Trust 0.02% 478 SH 11 सितमबर 2026 दैनिक
LGDX · Tidal Trust III 0.02% 251 NS 31 जुलाई 2026 N-PORT
GTOS · Invesco Actively Managed Exchange-T… 0.02% 21000 5 अक्टूबर 2026 दैनिक
GTO · Invesco Actively Managed Exchange-T… 0.01% 419000 2 अक्टूबर 2026 दैनिक
PEVC · Pacer Funds Trust 0.01% 3 NS 31 जुलाई 2026 N-PORT
NEAR · iShares U.S. ETF Trust 0.01% 600000 SH 11 सितमबर 2026 दैनिक
DFVX · Dimensional ETF Trust 0.01% 517 NS 31 जुलाई 2026 N-PORT
BIV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BLV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BSV · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
BND · VANGUARD BOND INDEX FUNDS · · 15 जुलाई 2026 दैनिक
VCRB · VANGUARD MALVERN FUNDS · · 15 जुलाई 2026 दैनिक
VPLS · VANGUARD MALVERN FUNDS · · 15 जुलाई 2026 दैनिक
VSDB · VANGUARD MALVERN FUNDS · · 15 जुलाई 2026 दैनिक
VGMS · VANGUARD MALVERN FUNDS · · 15 जुलाई 2026 दैनिक
VCSH · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VCIT · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VCLT · VANGUARD SCOTTSDALE FUNDS · · 15 जुलाई 2026 दैनिक
VTC · VANGUARD SCOTTSDALE FUNDS · · 30 जुलाई 2026 दैनिक
BNDW · VANGUARD SCOTTSDALE FUNDS · · 30 जुलाई 2026 दैनिक
VCEB · VANGUARD WORLD FUND · · 30 जुलाई 2026 दैनिक

CVS विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

21
रेटिंग · 33 विश्लेषक खरीदें
मध्यिका लक्ष्य $116.00 +34.2%
8 24.2% मजबूत खरीद
20 60.6% खरीदें
5 15.2% होल्ड
0 0.0% बेचें
0 0.0% मजबूत बिक्री

12-महीने का मूल्य लक्ष्य

25 विश्लेषक · 2026-10-05

माध्य लक्ष्य $116.28 +34.5%

← सभी लक्ष्यों से नीचे वर्तमान मूल्य $86.43
निम्न$103.00 माध्य$116.28 उच्च$148.00

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

22

वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
CVS $100.87B 57.1 7.8% 0.44% 2.4% ·
CI $72.51B 12.4 11.2% 2.2% 14.4% ·
DGX $19.09B 19.8 11.8% 9.0% 14.2% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
GH $13.34B -30.8 32.9% -42.4% 205.7% ·
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8% ·
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
HIMS · 63.7 59.0% 5.5% 23.3% 73.8%
CHE · 23.3 4.1% 10.5% 24.4% ·

ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां

23

ट्रेडिंग सिग्नल प्रवेश मूल्य और जोखिम/इनाम अनुपात के साथ हालिया खरीद/बिक्री संकेत

25

अभी कोई खुला सिग्नल नहीं — कोई कार्ड भरा नहीं है, और यह ईमानदार है।

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

26

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

स्रोत: SEC 10-Q अग 5, 2026 को फाइल किया गया